Cargando…

Attenuated measles virus as a vaccine vector

Live attenuated measles virus (MV) vaccines have an impressive record of safety, efficacy and ability to induce life-long immunity against measles infection. Using reverse genetics technology, such negative-strand RNA viruses can now be rescued from cloned DNA. This technology allows the insertion o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuniga, Armando, Wang, ZiLi, Liniger, Matthias, Hangartner, Lars, Caballero, Michael, Pavlovic, Jovan, Wild, Peter, Viret, Jean Francois, Glueck, Reinhard, Billeter, Martin A., Naim, Hussein Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707277/
https://www.ncbi.nlm.nih.gov/pubmed/17303293
http://dx.doi.org/10.1016/j.vaccine.2007.01.064
_version_ 1782276492843024384
author Zuniga, Armando
Wang, ZiLi
Liniger, Matthias
Hangartner, Lars
Caballero, Michael
Pavlovic, Jovan
Wild, Peter
Viret, Jean Francois
Glueck, Reinhard
Billeter, Martin A.
Naim, Hussein Y.
author_facet Zuniga, Armando
Wang, ZiLi
Liniger, Matthias
Hangartner, Lars
Caballero, Michael
Pavlovic, Jovan
Wild, Peter
Viret, Jean Francois
Glueck, Reinhard
Billeter, Martin A.
Naim, Hussein Y.
author_sort Zuniga, Armando
collection PubMed
description Live attenuated measles virus (MV) vaccines have an impressive record of safety, efficacy and ability to induce life-long immunity against measles infection. Using reverse genetics technology, such negative-strand RNA viruses can now be rescued from cloned DNA. This technology allows the insertion of exogenous genes encoding foreign antigens into the MV genome in such a way that they can be expressed by the MV vaccine strain, without affecting virus structure, propagation and cell targeting. Recombinant viruses rescued from cloned cDNA induce immune responses against both measles virus and the cloned antigens. The tolerability of MV to gene(s) insertion makes it an attractive flexible vector system, especially if broad immune responses are required. The fact that measles replication strictly occurs in the cytoplasm of infected cells without DNA intermediate has important biosafety implications and adds to the attractiveness of MV as a vector. In this article we report the characteristics of reporter gene expression (GFP, LacZ and CAT) and the biochemical, biophysical and immunological properties of recombinant MV expressing heterologous antigens of simian immunogeficiency virus (SIV).
format Online
Article
Text
id pubmed-3707277
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-37072772013-07-10 Attenuated measles virus as a vaccine vector Zuniga, Armando Wang, ZiLi Liniger, Matthias Hangartner, Lars Caballero, Michael Pavlovic, Jovan Wild, Peter Viret, Jean Francois Glueck, Reinhard Billeter, Martin A. Naim, Hussein Y. Vaccine Article Live attenuated measles virus (MV) vaccines have an impressive record of safety, efficacy and ability to induce life-long immunity against measles infection. Using reverse genetics technology, such negative-strand RNA viruses can now be rescued from cloned DNA. This technology allows the insertion of exogenous genes encoding foreign antigens into the MV genome in such a way that they can be expressed by the MV vaccine strain, without affecting virus structure, propagation and cell targeting. Recombinant viruses rescued from cloned cDNA induce immune responses against both measles virus and the cloned antigens. The tolerability of MV to gene(s) insertion makes it an attractive flexible vector system, especially if broad immune responses are required. The fact that measles replication strictly occurs in the cytoplasm of infected cells without DNA intermediate has important biosafety implications and adds to the attractiveness of MV as a vector. In this article we report the characteristics of reporter gene expression (GFP, LacZ and CAT) and the biochemical, biophysical and immunological properties of recombinant MV expressing heterologous antigens of simian immunogeficiency virus (SIV). Elsevier Ltd. 2007-04-20 2007-02-02 /pmc/articles/PMC3707277/ /pubmed/17303293 http://dx.doi.org/10.1016/j.vaccine.2007.01.064 Text en Copyright © 2007 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Zuniga, Armando
Wang, ZiLi
Liniger, Matthias
Hangartner, Lars
Caballero, Michael
Pavlovic, Jovan
Wild, Peter
Viret, Jean Francois
Glueck, Reinhard
Billeter, Martin A.
Naim, Hussein Y.
Attenuated measles virus as a vaccine vector
title Attenuated measles virus as a vaccine vector
title_full Attenuated measles virus as a vaccine vector
title_fullStr Attenuated measles virus as a vaccine vector
title_full_unstemmed Attenuated measles virus as a vaccine vector
title_short Attenuated measles virus as a vaccine vector
title_sort attenuated measles virus as a vaccine vector
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707277/
https://www.ncbi.nlm.nih.gov/pubmed/17303293
http://dx.doi.org/10.1016/j.vaccine.2007.01.064
work_keys_str_mv AT zunigaarmando attenuatedmeaslesvirusasavaccinevector
AT wangzili attenuatedmeaslesvirusasavaccinevector
AT linigermatthias attenuatedmeaslesvirusasavaccinevector
AT hangartnerlars attenuatedmeaslesvirusasavaccinevector
AT caballeromichael attenuatedmeaslesvirusasavaccinevector
AT pavlovicjovan attenuatedmeaslesvirusasavaccinevector
AT wildpeter attenuatedmeaslesvirusasavaccinevector
AT viretjeanfrancois attenuatedmeaslesvirusasavaccinevector
AT glueckreinhard attenuatedmeaslesvirusasavaccinevector
AT billetermartina attenuatedmeaslesvirusasavaccinevector
AT naimhusseiny attenuatedmeaslesvirusasavaccinevector